within Pharmacolibrary.Drugs.ATC.P;

model P01BB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.00038333333333333334,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.342,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01BB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Proguanil is an antimalarial drug, primarily used for the prevention and treatment of malaria, often in combination with atovaquone. It acts by inhibiting dihydrofolate reductase in the malaria parasite. Proguanil is still approved and in clinical use for malaria prophylaxis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose of proguanil.</p><h4>References</h4><ol><li><p>Plöger, GF, et al., &amp; Dressman, JB (2018). Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. <i>Journal of pharmaceutical sciences</i> 107(7) 1761–1772. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2018.03.009&quot;>10.1016/j.xphs.2018.03.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29571740/&quot;>https://pubmed.ncbi.nlm.nih.gov/29571740</a></p></li><li><p>Yang, E, et al., &amp; Lee, S (2023). Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. <i>Clinical pharmacokinetics</i> 62(4) 599–608. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01228-4&quot;>10.1007/s40262-023-01228-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36897544/&quot;>https://pubmed.ncbi.nlm.nih.gov/36897544</a></p></li><li><p>Morris, CA, et al., &amp; Fleckenstein, L (2011). Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. <i>Malaria journal</i> 10 263–None. DOI:<a href=&quot;https://doi.org/10.1186/1475-2875-10-263&quot;>10.1186/1475-2875-10-263</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21914160/&quot;>https://pubmed.ncbi.nlm.nih.gov/21914160</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01BB01;
